Go to Client Portal
NAMSA

Archives: Resources

Clinical Data Requirements Under MDR: A Panel Discussion

By

Navigating Dual Regulations: Strategies for IVD Market Approval in China and the EU

By

Considerations for Navigating ISO 22442-3 Viral Inactivation Studies

By

Comprehensive Guidance On Reusable Medical Device Processing Requirements: Cleaning, Disinfection and Sterilization Validations

By

Preclinical Considerations: Testing Regulated Wound Healing Devices

By

NAMSA Corporate Capabilities

By

Ex Vivo and In Vitro Tissue Models: Applications Supporting an Early Indication of Therapeutic Outcome

By

ISO 10993-17 2023 Update: What You Need to Know

By

Infectious Disease Diagnostic Devices: The Move to at Home Testing and Treatment (Panel Discussion)

By

The Chemical Characterization Puzzle: Is There a Solution?

By

When Innovation Outpaces Standardization – Solutions to Support Novel Wound Care Product Development

By

Biofilm Basics and Beyond

By

The FDA’s Draft Guidance on AI- and ML-Enabled Device Software Functions

By

Telling Your Medical Device’s Story to Regulatory Agencies

By

Clinical Trial Site Budgeting – Risk Mitigation or Budget Control?

By

A Practical Guide to Writing Summaries of Safety and Clinical Performance

By

Navigating Trends and Best Practices for Cardiovascular Device Development

By

MedTech Chats: MEGA BIOPHARMA Partners with NAMSA to De-Risk Disruptive Dental Technology

By

The Relationship Between Risk Management and Labeling

By

Exhaustive Extractions in E&L Studies – Endpoint Determination Challenges, Expectations and Reality

By

Navigating the Landscape for Over-the-Counter or Direct-to-Consumer IVD Tests

By

Optimizing Preclinical Testing for Cardiovascular Medical Devices

By

Biostatistics in IVD Clinical Research – Decoding the Biostatistical Black Box

By

Expanding your Market: Submitting U.S. EUA COVID-19 Products for EU IVDR Compliance

By

Chemical Characterization Best Practices: Assumptions of TTC and Exhaustive Extraction

By

FDA QMSR: What do the Proposed Changes Mean for Industry?

By

In Vitro Testing Strategies for Microbial Barrier Effectiveness

By

FDA and NAMSA Present: Reducing Regulatory Burden and Streamlining FDA Review through ASCA Pilot Program Utilization

By

ISO 14155:2020 – What Every Clinical Professional Should Know

By

The Basics of IVDR Clinical Studies

By

NAMSA Lab Equipment and Facilities

By

Transitioning from EUA to 510(k) for IVD Products: Planning to Execution

By

NAMSA Brochure Japanese

By

NAMSA Brochure

By

NAMSA Histology Laboratory

By

Pathology Assessment Of Medical Devices: Understanding the Basics

By

ASCA Accreditation for Biocompatiblity Testing: What’s it All About?

By

NAMSA Preclinical Research: Recommendations for the Evaluation of Investigational Heart Valve Technologies

By

The EU In Vitro Diagnostic Regulation (IVDR): Clarification Regarding Commonly Asked Questions

By

Analysis of Medical Claims Data for Economic Summaries and Alternative Uses

By

The Critical Role of Biostatistics in Streamlining the Preclinical to Clinical Pathway

By

Alternative Test Methods for Medical Device Sterilization Validation: An Industry Panel Discussion

By

SaMD Product Development: Addressing Challenges through Early Integration of Regulatory, Quality and Clinical Data Strategies

By

Key Factors for Successful Clinical Study Database Design and Data Management

By

MDR Clinical Evaluation Reports: Key Elements and Lessons Learned for Successful Compliance

By

ISO 10993-23:2021 Tests For Irritation – What Manufacturers Must Understand Today

By

IVDD to IVDR: How to Successfully Make the Transition

By

IVDR Implementation: First Steps for Compliance for Products Already on the European Market

By

EUDAMED Actor Registration Module: A Step Towards Greater Medical Device and IVD Product Safety and Transparency

By

Achieving EU and U.S. Commercialization Success: The Critical Linkage Between Reimbursement and Regulatory Strategies

By

Strategies for Selecting the Right In Vivo Models for Regulated Preclinical Studies

By

NAMSA Guide: The Design of Clinical Trials for CLIA-Waived Point-of-Care Tests

By

Reimbursement Opportunities and Challenges : Factors for Success – A NAMSA and Kalms Consulting sponsored Q&A Panel Discussion

By

Ensuring your Post-Market Surveillance Process Meets the New ISO 14971:2019 Guidance and MDR/IVDR Requirements

By

Considerations for Clinical Study Start-Up in a Virtual Environment

By

Navigating Clinical Trials in the Era of COVID-19: An Assessment of Short-Term and Long-Term Strategies

By

Achieving Medical Device Development Success Through Early Implementation of Regulatory, Reimbursement and Clinical Research Strategies

By

Transitioning from EUA to 510(k) Clearance for IVD Products: What to Expect

By

IVD Clinical Trials: Effective Site Selection Techniques – A Site and CRO Perspective

By

EU MDR Part 2: How to Approach Clinical Evidence Requirements with Clinical Management & Biostatistics

By

PharmaTech Outlook: Advancing Global Patient Healthcare through Full Continuum CRO Services for Medical Device Sponsors

By

NAMSA Guide: How to Design & Develop EDC Systems for Optimal IVD Clinical Trial Management

By

NAMSA Start-Up 360: Accelerating IVD Product Development

By

How to Manage Clinical Study Data During the COVID-19 Pandemic

By

EU MDR Part 1: Current Opportunities & Challenges with Clinical Data-A NAMSA Panel Discussion

By

Do’s & Don’ts for Early-Stage IVD Product Development & Risk Mitigation

By

Optimizing Electronic Data Capture (EDC) for IVD Clinical Trials

By

The COVID-19 Pandemic: Proper Clinical Study Management & Protecting Data Validity

By

Risk Management Systems: Implications of ISO 14971, ISO/TR 24971 & EU MDR Updates

By

The Value of Biostatistics: Bringing a New Medical Device to Market

By

4 Pillars of IVDR: Integrating Post-Market Surveillance, Risk Management, QMS & Performance Evaluation

By

The New ISO 10993-18:2020 – 10 Things Manufacturers Need to Know Today

By

Software as a Medical Device (SAMD): Qualifications & Regulatory Requirements

By

Virtual Vascular Company Partners with NAMSA to Accelerate 510(k) Clearance by 30 Percent

By

The Biological Evaluation Plan: How can a Step-Wise Approach Create Resource Efficiencies?

By

Human Factors: Global Considerations & Regulatory Requirements

By

How to Successfully Launch IVD Products in China

By

Impacts of the Updated ISO 14971 & Harmonization of MDR/FDA Rules on Risk Management

By

Medical Device Biological Evaluation Reports: Relevance to ISO 10993-Part 1: 2018

By

Biostatistics in IVD Clinical Research: What can Make or Break your Product’s Commcercialization?

By

MDR 10.4.1: What Should we Really be Doing to be Prepared?

By

NAMSA Guide: In Vitro Diagnostic (IVDR) Readiness Guide

By

How to Implement an Effective Internal Audit Program

By

CMDE Draft Guidelines’ Impact on In Vitro Diagnostic Clinical Trials & Reagents

By

How to Select the Right EU Notified Body for IVDR Compliance

By

How to Select the Proper EU Notified Body for your Medical Device Organization

By

Use of OUS Clinical Data in Medical Device Product Development

By

Design Control: Understanding the Benefits of Starting Early & Why Its Necessary

By

Understanding Medical Device Reimbursement Fundamentals to Achieve Commercial Success

By

Clinical Research Services Brochure

By

Particulates in Preclinical Testing: Understanding the Impact on Overall Device Biological Safety

By

Medical Device Reimbursement Strategy: How to Plan for Successful Market Commercialization

By

Understanding & Applying ISO 19227 Requirements for Orthopedics Manufacturers

By

Medical Device Landscape Report: Trends and Challenges in Clinical Research Outsourcing

By

IVD Clinical Trials: Essential Components for Product Launch in 2019 & Beyond

By

EU MDR: General Safety & Performance Requirements for the Biocompatibility of Medical Devices

By

THE New ISO 10993-1: 2018 – What Now?

By

EU MDR 2017/745: Optimizing CERs within the Medical Device Lifecycle

By

How to Effectively Navigate Radiation Sterilization Validation Scenarios

By

Global Regulatory Requirements for Chemical Characterization: How to Cost-Effectively Demonstrate Biological Safety

By

Leveraging Post-Market Surveillance & Post-Market Clinical Follow-Up Data to Support EU MDR Compliance

By

The Effective Design & Development of Preclinical Studies

By

CFDA Acceptance of Overseas Clinical Trial Data: Understanding the Impact to Medical Device Manufacturers

By

ISO 10993-1: Understanding the Use & Value of Biocompatibility Safety Evaluation & Risk Assessment Standards for Medical Devices

By

NAMSA Guide: EU MDR & IVDR Regulation Tool

By

Leveraging Post-Market Surveillance & Clinical Follow-Up Data to Support EU MDR Compliance

By

NAMSA APEX Program™ Expedites 510(k) Clearance for Solvay Dental 360™, Delivers 12 Months & $7.5M in Development Savings

By

How to Use Real-World Evidence to Support Regulatory Decision-Making for Medical Devices

By

Effective Preparation & Implementation of Medical Device Quality Management Systems

By

Emerging Medical Device Markets in Latin America

By

Reducing Medical Device Development Timelines & Creating Value through Biological Risk Assessments & Chemical Characterization

By

Risk-Based Monitoring: Exploring the Clinical Site Experience

By

Biocompatibility Matrix

By

GLP & GMP Guide

By

Risk-Based Monitoring: Considerations for Clinical Implementation

By

Risk-Based Monitoring: Setting up the Structure for a Systematic Approach

By

Risk-Based Monitoring: A Cognizant Approach

By

Joining Preclinical and Clinical Development: A Practical Approach to Reducing Medical Device Timelines

By